tbuckley/cabot-search huggingface dataset:
High spatial and temporal resolution breast DCE-MRI: A feasibility study.
Authors: N. Roy, K. Y. Oh, M. D. Kettler, L. A. Tudorica, W. Huang
Journal: Journal of Clinical Oncology (2011)

74 Background: The typical 1-2 min low temporal resolution (tRes) of conventional gradient-echo (GRE) breast dynamic contrast-enhanced (DCE) MRI precludes accurate quantitative pharmacokinetic (PK) analysis. The commercially available GRE-based TWIST (time-resolved angiography with stochastic trajectories) sequence employs an alternative k-space sampling scheme to provide high spatial and temporal resolution for dynamic imaging, originally intended for time-resolved MR angiography. Here we sought to evaluate the feasibility of breast DCE-MRI with the TWIST sequence, using both tumor morphology and quantitative PK analyses. Methods: 22 patients with 25 mammography-detected suspicious lesions underwent TWIST DCE-MRI on a 3T Siemens system prior to biopsy. The axial bilateral images were acquired with 20 s tRes and 1.0x1.0x1.4 mm 3 spatial resolution (sRes). Immediately after TWIST DCE-MRI, a single DCE image set was acquired in 68 s using a conventional GRE sequence with the same sRes. Blinded to pathology, 3 radiologists compared lesion morphology assessments from the last TWIST DCE and the conventional images, and gave MRI BIRADS scores based on morphology and qualitative kinetic curve analyses. The TWIST DCE lesion signal time-courses were also subjected to Shutter-Speed Model PK analysis. Results: Normal parenchyma S/N ratios were not statistically different between TWIST and conventional GRE images. All readers indicated 88% [95% CI: (68%, 97%)] agreement in morphology evaluation between the TWIST and conventional DCE images. The degree of inter-reader agreement was substantial (κ = 0.75), as was the agreement in BIRADS scores (κ = 0.76). Pathology revealed 8 malignant and 17 benign lesions. Based on MRI BIRADS scores, all 3 readers attained 100% sensitivity and 82% specificity. With PK analysis, a K trans (contrast agent plasma/interstitium transfer rate constant) cut-off value of 0.1 min -1 further improved specificity to 94%. Conclusions: TWIST breast DCE-MRI provides both high tRes and sRes for accurate quantitative PK analysis and morphology evaluation, respectively. Utilizing TWIST for clinical breast DCE-MRI with quantitative PK analysis is feasible and may improve MRI interpretation.
Flow Cytometric Detection and Phenotype of Circulating CD34+ Cells in Patients Affected by Chronic Lymphocytic Leukemia.
Authors: Fabio Stagno, Nunziata Laura Parrinello, Giovannella Fargione, Anna Triolo, Antonella Privitera, Elisa Seria, Francesca Mannino, Francesco Di Raimondo, Patrizia Guglielmo, Rosario Giustolisi
Journal: Blood (2005)
Survey on management of metastatic hormone-refractory prostate cancer upon progression during or following first-line chemotherapy in five European countries.
Authors: Sebastien Auziere, Alain Flinois, Eliot Obi-Tabot, Mathieu Rose, Adam Parnaby
Journal: Journal of Clinical Oncology (2012)

e15198 Background: In Europe, docetaxel is the standard first-line chemotherapy (1L) for patients with metastatic hormone-refractory prostate cancer (mHRPC). Upon progression, either during or after 1L chemotherapy, treatment options are limited. This study evaluated how patients who progressed during or after 1L docetaxel between Oct 2009 and Jun 2010 were managed. Methods: A representative sample of 349 physicians (oncologists, urologists) who managed patients with mHRPC selected from Germany, France, UK, Spain and Italy were surveyed. Information on the treatments used at the time of progression (during or within the first 6 months following 1L treatment with docetaxel was provided. Results: Information on a total of 2,870 mHRPC patients was provided of which 2,670 (94 %) had received docetaxel in 1L. 1,389 (52%) patients progressed during 1L docetaxel or within 6 months following treatment; of these, 615 (44 %) received as 2L chemotherapy (Table). Conclusions: In this study, mitoxantrone was the most commonly used chemotherapy agent for 2L treatment of patients with mHRPC who progressed during treatment or within the first 6 months following the end of 1L. Docetaxel rechallenge was uncommon for patients experiencing progression early, during or after the end of 1L. [Table: see text]
Low-Dose Arsenic Trioxide Combined with Aclacinomycin a Synergistically Enhance the Cytotoxic Effect on Human Acute Myelogenous Leukemia KG-1a Cell Line By the Induction of Apoptosis
Authors: Yongbin Ye, Xiaojun Xu, Mingwan Zhang, Dafa Qiu, Xiaochun Bai, Jing Wang, Guangyang Weng, Zhou Ruiqing, Ziwen Guo, Huiqing He, Wenfang Yi, Xin He, Guo Kunyuan
Journal: Blood (2014)
European Leukemianet (ELN) Project Diagnostic Platform (WP10): Final Results of the First Study of the European Morphology Consensus Panel.
Authors: Gina Zini, Barbara Bain, Gianluigi Castoldi, José Cortez, Judit Csomor, Edgar Faber, Aristoteles Giagounidis, Torsten Haferlach, Petra Kacirkova, Krzysztof Lewandowski, Vincenzo Liso, Estella Matutes, Marc Maynadie, John Meletis, Anna Porwit, M. Leticia Ribeiro, Lydia Sreter, Andre Tichelli, Teresa Vallespì, Mars B. van ‘t Veer, Soledad Woessner, Marie-Christine Bene
Journal: Blood (2008)
The prevalence of triple-negative breast cancer in Thai patients.
Authors: N. Parinyanitikul, V. Tanakit, P. Sungkasubun, S. Manasnayakorn, T. Raiyawa, V. Sriuranpong
Journal: Journal of Clinical Oncology (2011)

e11541 Background: Triple-negative breast cancer certainly becomes the interested subgroup of breast cancer because of poorer outcomes. In term of clinicopathologic features, response rate in chemotherapeutic agents and survival outcomes relatively differ from hormone positive and HER-2 positive groups. So we would like to identify the prevalence and epidemiologic data of this subgroup in Thai patients and compare to several datas. Methods: One hundred and fifty-three triple negative breast cancer patients diagnosed and treated at the King Chulalongkorn Memorial Hospital during 2003-2010 were retrospectively reviewed. The clinicopathologic features were collected from medical records. In addition, the outcomes of chemotherapy treatment and survival rate were analyzed. Results: Invasive ductal carcinoma was identified 86.9%. Average age was 47.9 years. (Range 26-79 years) Early and locally advanced stages were found 77.6% and 19.1%, respectively. The clinicopathologic features were high grade (70%), tumor size T2 54.7%, p53 positive 67%, Ki-67 positive 97% (Ki-67 more than 30% in 78.6%), lymphatic invasion 40.3%, LN negative 59.2%. 62.9% underwent modified radical mastectomys. Axillary node resections were performed 86.3%. In neoadjuvant treatment subgroup (45 patients), anthracycline-based regimens were prescribed in 88.9% and overall response rate was 77.8%, particularly pCR 24.4%. After average 34 months follow-up (Range 3-120 months), twenty-nine death patients were observed. Most common sites of recurrence were visceral, lung and brain metastases. Conclusions: The prevalence and clinicopathologic features of triple-negative breast cancer in Thai patients were similar to the results previously published by other researchers. Chemotherapy treatment outcomes in this subgroup had significantly identified better than hormone positive group.
Detection of Residual p73 DNA Methylation Predicts for Shorter Disease Free and Overall Survival in Patients (pts) with Philadelphia (Ph) Chromosome Negative Acute Lymphocytic Leukemia (ALL) in Remission.
Authors: Guillermo Garcia-Manero, Carlos Bueso-Ramos, Lianchun Xiao, Koyu Hoshino, Gary Rosner, Sherry Pierce, Hui Yang
Journal: Blood (2006)
Is modified Bloom-Richardson grade a reliable predictor of breast cancer recurrence?
Authors: K. K. L. Yap, D. N. Efiom-Ekaha
Journal: Journal of Clinical Oncology (2011)

52 Background: Modified Bloom-Richardson (MBR) grade is a pathologic grading system for breast cancer that has been shown to have prognostic significance in patients with node-negative disease. Oncotype DX Score is a 21-gene expression analysis that has been clinically validated as a reliable predictor of recurrence risk for node-negative estrogen receptor-positive breast cancer. A score of less than 18 signifies a low risk of recurrence, a score of 18 to 31 signifies an intermediate risk and a score greater than 31 signifies a high risk. Several reports have questioned the concordance between the Oncotype score and MBR grade. The objective of this study is to evaluate the concordance between Oncotype score and MBR grade, thereby ascertaining if MBR is a reliable predictor of breast cancer recurrence. Methods: An IRB-exempted restrospective chart review of female patients at Wellspan Group who had Oncotype DX analysis in 2008 and 2009 was carried out. Data collected included Oncotype DX score, MBR grade, BMI and menopausal status. Data were analyzed to determine the association between Oncotype DX score and MBR grade. Results: A total of 125 patients were identified. Of these, 107 had MBR grades available. The remaining patients did not have MBR grade as it was not applicable to their breast cancer type. The mean Oncotype scores were 15.11 (95% CI 13.33-16.89) for patients with MBR grade 1 carcinoma, 20.31 (95% CI 17.90-22.72) for MBR grade 2 carcinoma, and 39.93 (95% CI 30.05-49.80) for MBR grade 3 carcinoma. The mean Oncotype score differences were 5.201 (P = .007, 95% CI 1.46-8.94) between MBR grades 1 and 2, and 19.616 (P &lt; 0.001, 95% CI 14.14-25.09) for MBR grades 2 and 3. The ranges of Oncotype scores for MBR grade 1, grade 2 and grade 3 were 3 to 36, 9 to 56 and 20 to 70 respectively. Conclusions: MBR grade may predict breast cancer recurrence risk reliably as there is acceptable concordance between MBR grade and Oncotype Dx recurrence risk.
MiR-29 MicroRNAs Regulate IGF-1R Expression and Contribute Mantle Cell Lymphoma Growth and Survival.
Authors: Jianhong Lin, Jianjun Zhao, Tint Lwin, Crespo Luis, Fangxia Guan, Sophie Dessureault, Lynn C. Moscinski, William S. Dalton, Eduardo M. Sotomayor, Jin Cheng, Jianguo Tao
Journal: Blood (2009)
Generation of Prothrombinase According to Hicks and Pitney Test. Comparison of the Levels of F1+2 Simultaneously in Hemophiliacs with and without Thrombophilic Mutations and Normal Subjects.
Authors: Pantelis P.E.M. Makris, Fotios F.I.G. Girtovitis, Maria M.K.T. Tsaousidou, Eleftheria E.P. Pithara, Zoi Z.I.F. Foka, Michel Meyer M.M.S. Samama
Journal: Blood (2004)
Reduction in Immunoglobulin (IVIG or Anti D) Use in Patients with Chronic Immune Thrombocytopenic Purpura (ITP) Receiving AMG 531: Results from Two Phase 3 Randomized Placebo-Controlled Trials.
Authors: Vinod Pullarkat, Terry B. Gernsheimer, J. Th. M. de Wolf, Troy H. Guthrie, Adrian Newland, Jeffrey S. Wasser, Solomon I. Hamburg, Sue Gao, Ron Stewart, Janet L. Nichol
Journal: Blood (2007)
Hevylite® to Monitor Response to Therapy in Multiple Myeloma
Authors: Guillemette Fouquet, Susanna Schraen, Jean-Luc Faucompré, Lionel Karlin, Margaret Macro, Cyrille Hulin, Brigitte Onraed, Laurent Garderet, Murielle Roussel, Bertrand Arnulf, Brigitte Pegourie, Brigitte Kolb, Anne-Marie Stoppa, Sabine Brechignac, Mauricette Michallet, Gerald Marit, Claire Mathiot, Anne Banos, Mourad Tiab, Mamoun Dib, Jean-Gabriel Fuzibet, Marie-Odile Petillon, Philippe Rodon, Marc Wetterwald, Bruno Royer, Laurence Legros, Lofti Benboubker, Olivier Decaux, Denis Caillot, Martine Escoffre-Barbe, Jean-Paul Fermand, Philippe Moreau, Michel Attal, Hervé Avet-Loiseau, Thierry Facon, Xavier Leleu
Journal: Blood (2014)
Nomogram for predicting development of brain metastasis in patients with inflammatory breast cancer.
Authors: K. P. S. Raghav, B. N. Bekele, V. Valero, M. R. Matrana, N. K. Ibrahim
Journal: Journal of Clinical Oncology (2011)

243 Background: Inflammatory breast cancer (IBC) is associated with poor prognosis and high rates of distant metastasis. Brain metastasis is particularly important due to its morbidity and mortality. The purpose of this study was to construct a nomogram from clinicopathological factors that could predict the risk of occurrence of brain metastasis in patients with IBC. Methods: We performed a retrospective analysis of 406 patients with IBC, who were seen at the University of Texas M. D. Anderson Cancer Center between 1991 and 2009. Data was collected from IBC registry. Patients were divided in a randomized manner into a training cohort (n = 206) and a validation (n = 200) cohort. A multivariate cox proportional hazards regression analysis of selected prognostic features was performed on the training cohort. The model estimated in the training cohort was cross-validated with the validation cohort. Based on this model a nomogram was constructed to assess 5- and 10-year risk of developing brain metastasis. Results: A total of 115 (28%) patients developed brain metastasis. Univariate analysis identified menopausal status, progesterone receptor expression, number of distant metastasis, adjuvant taxane-based therapy and age at diagnosis as significant factors associated with brain metastasis (p &lt; 0.05). Subsequent multivariate analysis showed menopausal status and number of metastasis were independently associated with development of brain metastasis (p &lt; 0.05). Nomogram constructed using above model was evaluated for its ability to discriminate among likelihood of occurrence of brain metastasis in patients, using the validation set. The validation set showed good discrimination with the area under the receiver operating characteristic curve of 0.68. Conclusions: We have formulated a distinct predictive tool to evaluate 5 and 10-year risk for developing brain metastasis in patients with IBC. This nomogram can be potentially helpful for designing risk adapted therapeutic trials. Identifying patients at high risk for brain metastasis in IBC can help personalize therapy, surveillance, and prognostication. [Table: see text]
Cellular and Molecular Effects of NVP-BKM120 in Lymphoblastic Leukemia Cells
Authors: João Kleber Novais Pereira, João Agostinho Machado-Neto, Matheus Rodrigues Lopes, Fabiola Traina, Fernando Ferreira Costa, Sara Teresinha Olalla Saad, Patricia Favaro
Journal: Blood (2014)
Intercalated Cell Depletion and Vacuolar H+-ATPase Mistargeting in an Ae1 R607H Knockin Model
Authors: Rizwan Mumtaz, Francesco Trepiccione, J. Christopher Hennings, Antje K. Huebner, Bettina Serbin, Nicolas Picard, A. K. M. Shahid Ullah, Teodor G. Păunescu, Diane E. Capen, Rawad M. Lashhab, Isabelle Mouro-Chanteloup, Seth L. Alper, Carsten A. Wagner, Emmanuelle Cordat, Dennis Brown, Dominique Eladari, Christian A. Hübner
Journal: Journal of the American Society of Nephrology (2016)

Distal nephron acid secretion is mediated by highly specialized type A intercalated cells (A-ICs), which contain vacuolar H + -ATPase (V-type ATPase)-rich vesicles that fuse with the apical plasma membrane on demand. Intracellular bicarbonate generated by luminal H + secretion is removed by the basolateral anion-exchanger AE1. Chronically reduced renal acid excretion in distal renal tubular acidosis (dRTA) may lead to nephrocalcinosis and renal failure. Studies in MDCK monolayers led to the proposal of a dominant-negative trafficking mechanism to explain AE1-associated dominant dRTA. To test this hypothesis in vivo , we generated an Ae1 R607H knockin mouse, which corresponds to the most common dominant dRTA mutation in human AE1, R589H. Compared with wild-type mice, heterozygous and homozygous R607H knockin mice displayed incomplete dRTA characterized by compensatory upregulation of the Na + /HCO 3 − cotransporter NBCn1. Red blood cell Ae1-mediated anion-exchange activity and surface polypeptide expression did not change. Mutant mice expressed far less Ae1 in A-ICs, but basolateral targeting of the mutant protein was preserved. Notably, mutant mice also exhibited reduced expression of V-type ATPase and compromised targeting of this proton pump to the plasma membrane upon acid challenge. Accumulation of p62- and ubiquitin-positive material in A-ICs of knockin mice suggested a defect in the degradative pathway, which may explain the observed loss of A-ICs. R607H knockin did not affect type B intercalated cells. We propose that reduced basolateral anion-exchange activity in A-ICs inhibits trafficking and regulation of V-type ATPase, compromising luminal H + secretion and possibly lysosomal acidification.
Predicting possibility of positive non-sentinel nodes in sentinel node–positive breast cancer patients: A Singapore series.
Authors: W. S. Yong, M. H. Chang, W. J. J. Chen
Journal: Journal of Clinical Oncology (2011)

51 Background: Sentinel lymph node (SLN) biopsy is an accepted method for determining the axillary status in early breast cancer patients. If positive, a standard axillary clearance is performed. However, recent studies have shown that many of these patients may not have additional positive non sentinel nodes, and the removal of these additional nodes may not be necessary or confer any benefit. We set out to identify factors that determine non sentinel node positivity and whether this could be predicted from our series of early breast cancer patients. Methods: We retrospectively reviewed 337 of our early breast cancer patients from 2005 to 2008 who had atleast one positive sentinel node and had undergone a full axillary clearance. Tumour factors and sentinel node variables were collected and compared between those patients with additional positive non sentinel nodes and those with no positive nodes in the axillary clearance. Results: Five factors were found on univariate analysis to be associated with non sentinel node positivity. They are ratio of positive SLN to total number of SLN, number of positive SLNs, size of metastasis in the SLN, tumour size and lymphovascular invasion. The first 3 factors were used to model a logistic-regression model which has good prediction ability to predict positivity of non SLNs (value under ROC curve 0.726 [95% CI 0.666-0.786]). Conclusions: Tumor factors and SLN variables are able to help us predict the possibilty of additional positive non SLN once at least a SLN is positive. This can help the surgeon and patient in the decision making process on the need for a full axillary clearance.
Preventive effect of rikkunshito, traditional Japanese medicine, for chemotherapy-induced nausea and vomiting.
Authors: Shinya Kajiura, Ayumu Hosokawa, Hiroki Yoshita, Naokatsu Nakada, Yuko Itaya, Akira Ueda, Takayuki Ando, Haruka Fujinami, Kohei Ogawa, Toshiro Sugiyama
Journal: Journal of Clinical Oncology (2012)

135 Background: Supportive therapies are being developed for chemotherapy-induced nausea and vomiting (CINV). Rikkunshito is a Kanpo medicine, which is a part of traditionally practiced Japanese-based ancient Chinese medicine. It has been reported to be effective against cisplatin-induced anorexia in rats. In the present study, we evaluated the preventive effect of rikkunshito for CINV in patients receiving high-dose cisplatin. Methods: We selected subjects who received chemotherapy including cisplatin (≥60mg/m 2 ) for gastric or esophageal cancer between April 2008 and July 2011 at our institution. We targeted 26 cases treated without a reduction in the anti-cancer medication in the second course and added 7.5g/day of rikkunshito, orally administered for seven days, to their second course treatment regimen. All cases were treated with 5-HT 3 receptor antagonist and steroid, and 12 cases were treated with palonosetron for the prevention of CINV in their first and second courses. We evaluated the complete response (CR, defined as no emesis and no rescue medication) rate and other toxicity, according to CTCAE v4.0, of the first and second courses. Results: The median age of the patients was 67 years (range, 49–77 years). There were nine cases of gastric cancer and 17 cases of esophageal cancer. The chemotherapy regimens were cisplatin + irinotecan in two cases, cisplatin + 5-FU in 15 cases, cisplatin + S-1 in seven cases and cisplatin + 5-FU + docetaxel in two cases. Six cases received concomitant radiation therapy. Anorexia in the first course was grade 0/1/2 = 4/12/10, but had been mitigated in the second course to grade 0/1/2 = 11/11/4 (P = 0.020). CR rate was 69.3% in the first course (95% CI, 51.6%–87.0%) and by the second course had improved to 88.5% (95% CI, 76.2%–100%) (P = 0.089). And about the other major toxicity, there was no significant difference between first and second courses. Conclusions: These results suggest that rikkunshito has the potential to improve CINV in patients receiving high-dose cisplatin.
A Novel Biomarker for Inhibitor Risk Prediction-the HLA-II Bound and Unbound Components of FVIII Derived Peptides-Reveals a Protective Influence for N-Linked Glycosylation
Authors: Kevin R. Viel, Marco Hofmann, Sabine Zollner, Bernadette W. Luu, Rajalingam Raja, Jerry Sherman Powell, Eugene Maraskovsky, Tom E. Howard
Journal: Blood (2015)
Prognostic factors for progression-free and overall survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group.
Authors: F. Bertucci, J. Blay, I. L. Ray-Coquard, B. Bui Nguyen, A. Adenis, M. Rios, F. Duffaud, D. Cupissol, C. Chevreau, E. Bompas, A. Cioffi, L. Nehal, D. Perol, A. Le Cesne
Journal: Journal of Clinical Oncology (2011)

e20506 Background: The aim of this work was to investigate factors predicting progression-free survival (PFS) and overall survival (OS) of patients (pts) with advanced GIST treated with 400 mg/day IM included in the BFR14 study. Methods: 434 pts were included in this prospective multicenter trial from June 2002 to July 2009. After 1, 3 and 5 yrs of IM 400mg/day, pts free from progression were randomly offered to continue or interrupt (I arm) IM. Pts allocated to the I arm could restart IM (same dose) in case of progression. Pts declining randomization proceed with IM. Since time to secondary resistance to IM and OS were similar in both arms, prognostic factors for survival were therefore investigated in the entire cohort (randomized and not randomized pts) included in the BFR14. Survival was defined from the date of inclusion to the date of death for OS or to the first occurrence of progression or death for PFS. Baseline characteristics were tested in a univariate step. Variables statistically significant at 0.10 alpha-level were included in a multivariate Cox model. A backward stepwise procedure was used to identify independent prognostic factors for PFS then OS. Results: As of January 2011, after a median follow-up of 41.7 months (CI95% = [35.2 – 48.4]), there were 254 events (58.5%) and 134 deaths (30.9%). The 2 and 3-yrs PFS were 52% and 42% respectively. PS 0, normal platelets count and CD34-positivity on tumor cells were the three independent prognostic factors of a higher PFS. The 2 and 3-yrs OS were 83% and 73% respectively. A higher OS was independently predicted by sex (female), PS (0), platelets count (<400 giga/L) and lymphocytes count (>1,500/mm3). Mutational analysis is ongoing. Conclusions: In this large series of advanced GIST pts treated with standard dose IM, pts with a good PS and normal platelet counts have a favourable outcome, both on PFS and OS. GIST expressing CD34 have a better PFS. Male GIST pts and pts with lymphopenia have a dismal OS.
Lysosomal Degradation of CD33, the Target for the Anti-Leukemia Immunoconjugate, Gemtuzumab Ozogamicin: Evidence for Cbl-Mediated Monoubiquitination.
Authors: Roland B. Walter, Brian W. Raden, Darren M. Kamikura, Irwin D. Bernstein, Jonathan A. Cooper
Journal: Blood (2005)